

Supplementary Table 1. Antibiotic susceptibility of ten KPC-KP isolates included in this study

| | | | MIC (mg/l) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---------|-----------|-------------------|------------|---|-----|---|-----|---|-----|---|-----|---|-------|---|--------|---|-----|---|-----|---|---------|---|-----|---|-----|---|-----|---|-------|---|------|---|------|---|--------|--|
| Patient | Isolate | Date of isolation | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | ERT* | | MEM | | IMI | | AMK | | GEN | | AMC | | PT | | FEP | | CAZ | | CAZ-AVI | | CRO | | CIP | | LEV | | TGC | | COL | | FOS | | SXT | |
| 1 | RM2.05.T0 | 16/02/2018 | >2 | R | >64 | R | >8 | R | 16 | R | ≤1 | S | >64/2 | R | >128/4 | R | >16 | R | >64 | R | 16/04 | R | >4 | R | >1 | R | >8 | R | 0.5 | S | >4 | R | >256 | R | >8/152 | |
| 2 | RM2.10.T0 | 22/08/2018 | >2 | R | 2 | S | ≤1 | S | >16 | R | >8 | R | 16/2 | R | 8/4 | S | >16 | R | >64 | R | >64/4 | R | >4 | R | >1 | R | >8 | R | ≤0.25 | S | 1 | S | 16 | S | ≤1/19 | |
| 3 | RM2.15.T0 | 24/11/2018 | >2 | R | 2 | S | ≤1 | S | 16 | R | ≤1 | S | >64/2 | R | >128/4 | R | >16 | R | >64 | R | 64/4 | R | >4 | R | >1 | R | >8 | R | 0.5 | S | ≤0.5 | S | >256 | R | >8/152 | |
| | RM2.15.T4 | 05/04/2019 | >2 | R | >64 | R | >8 | R | >16 | R | ≤1 | S | >64/2 | R | >128/4 | R | >16 | R | >64 | R | 8/4 | S | >4 | R | >1 | R | >8 | R | 0.5 | S | ≤0.5 | S | 64 | R | ≤1/19 | |
| 4 | RM2.21.T0 | 21/02/2019 | >2 | R | >64 | R | >8 | R | >16 | R | 4 | R | >64/2 | R | >128/4 | R | >16 | R | >64 | R | 16/4 | R | >4 | R | >1 | R | >8 | R | 0.5 | S | 1 | S | 32 | S | >8/152 | |
| | RM2.21.T4 | 21/06/2019 | >2 | R | 32 | R | 4 | I | >16 | R | ≤1 | S | >64/2 | R | >128/4 | R | >16 | R | >64 | R | 4/4 | S | >4 | R | >1 | R | >8 | R | 0.5 | S | ≤0.5 | S | 8 | S | >8/152 | |
| | RM2.21.T8 | 25/11/2019 | >2 | R | >64 | R | >8 | R | >16 | R | >8 | R | >64/2 | R | >128/4 | R | >16 | R | >64 | R | 2/4 | S | >4 | R | >1 | R | >8 | R | 0.5 | S | 1 | S | 32 | S | >8/152 | |
| 5 | RM2.31.T0 | 22/05/2019 | >2 | R | 1 | S | ≤1 | S | >16 | R | >8 | R | 16/2 | R | 16/4 | R | 16 | R | >64 | R | 32/4 | R | >4 | R | >1 | R | >8 | R | ≤0.25 | S | ≤0.5 | S | >256 | R | ≤1/19 | |
| | RM2.31.T4 | 16/09/2019 | 2 | R | 1 | S | ≤1 | S | >16 | R | >8 | R | 32/2 | R | 16/4 | R | 16 | R | >64 | R | 64/4 | R | >4 | R | >1 | R | >8 | R | ≤0.25 | S | ≤0.5 | S | >256 | R | ≤1/19 | |
| 6 | RM2.71.T0 | 30/01/2020 | >2 | R | 1 | S | ≤1 | S | >16 | R | >8 | R | 16/2 | R | 16/4 | R | >16 | R | >64 | R | 32/4 | R | >4 | R | >1 | R | >8 | R | ≤0.25 | S | ≤0.5 | S | >256 | R | ≤1/19 | |

*Resistant isolates are marked in bold; ERT, ertapenem; MEM, meropenem; IMI, imipenem; AMK, amikacin; GEN, gentamicin; AMC, amoxicillin/clavulanic; PT, piperacillin/tazobactam; FEP, cefepime; CAZ, ceftazidime; CAZ-AVI, ceftazidime/avibactam; CRO, ceftriaxone; CIP, ciprofloxacin; LEV, levofloxacin; TGC, tigecycline; COL, colistin; FOS, fosfomycin; SXT trimethoprim-sulfamethoxazole.